



Docket No. JAB-1409

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Ed y J.F.krayne et al. Applicants:

Serial No. :

Filed

March 19, 2001

* Examiner: J.Ford

IL-5 INHIBITING 6-AZAURACIL DERIVATIVES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

December 5, 2001

(Date)

Ellen Ciambrone Coletti

Name of applicant / assignee, or Register **c**esentative

December 5, 2001

(Date of Signature)

Commissioner for Patents Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Office Action mailed November 7, 2001.

In the Office Action, restriction is required to one of the following:

Claims 1-11 drawn to certain-as-triazines. (I)

- (II) Claim 12 drawn to an actual method of making the composition.
- (III) Claims 13 and 14.
- (IV) Claim 15 a different-as-triazine.
- (V) Claim 16 multiple processes of preparing the compounds of claim 1.
- (VI) Claim 17 drawn to a process of radiolabelling.
- (VII) Claim 18 drawn to a method of imaging an organ.

Applicants hereby elect the subject matter of Group I, that is, claims 1-11.

Early favorable consideration of the application is requested.

Respectfully submitted,

Ellen Ciambrone Coletti

Req. No. 34,140

Attorney for Applicant(s)

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-2359 December 5, 2001